LUPUS NEPHRITIS (LN)
Clinical trials for LUPUS NEPHRITIS (LN) explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS (LN) trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS (LN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
Disease control Not yet recruitingThis early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells aim to tame Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on lupus kidney disease in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called C-CAR168 for people with lupus nephritis that hasn't improved with standard therapies. C-CAR168 is made from a patient's own immune cells, which are modified to target and attack faulty immune cells. The study will enroll 24 adu…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat lupus kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC